Biocon has completed the acquisition of an additional 7,18,34,691 equity shares in Biocon Biologics Limited (BBL) from Mylan Inc. The acquisition was completed on January 21, 2026, with a cash consideration of USD 200 million. Following this acquisition, Biocon now holds approximately 98% of the paid-up equity share capital of BBL on a fully diluted basis. This move strengthens Biocon’s position in its biologics business.
Acquisition Completion
Biocon has finalized the acquisition of additional equity shares of Biocon Biologics Limited (BBL), from Mylan Inc. The company had previously announced its intention to acquire a total of 14,36,69,382 equity shares in BBL.
Details of the Transaction
The acquisition was completed on January 21, 2026, with a cash consideration of USD 200 million for the acquisition of 7,18,34,691 equity shares. This follows an earlier acquisition of 7,18,34,691 equity shares from Mylan Inc. announced on January 05, 2026.
Post-Acquisition Holding
Following the completion of this acquisition, Biocon now holds approximately 98% of the paid-up equity share capital of BBL on a fully diluted basis. The initial agreement involved a total cash consideration of USD 400 million for all the shares.
Source: BSE
